All In Biotech

Drug Trial Radar · NCT06717126

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

A Phase II, Multi-centre, Open Label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib in Patients With Advanced/Metastatic Ocular/Uveal Melanoma

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
iOncturaIndustry
Sponsor type
Industry
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?

Conditions

  • Uveal Melanoma
  • Ocular Melanoma

Interventions

  • roginolisibDrug

    rognolisib

  • Investigator choice of standard therapyDrug

    Investigator will choose the most appropriate treatment standardly given to patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: Patients will be followed up for overall survival every 12 weeks, for 96 weeks from last patient enrolled, until their death or end of the study

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • SSD Tumori Rari e Melanoma Viale Orazio Flacco

    Bari, Italy

  • IRCSS National Cancer Institute, "G.Pascale" Foundation Dip. CORP-S di Ricerca ed Assistenziale Cute, Melanoma lmmunologia Oncologica Sperimentale e Terapie Innovative

    Naples, Italy

  • IRCSS Istituto Oncologico Veneto UOS Oncologia 2 del Melanoma Ospedale Busonera

    Padova, Italy

  • IRCCS Istituto Clinico Humanitas

    Rozzano, Italy

  • A.O.U.S. Santa Maria delle Scotte

    Siena, Italy

  • Institut Catala d'Oncologia - ICO L'Hospitalet

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Complejo Hospitalario Universitario de Santiago - CHUS

    Santiago de Compostela, Spain

  • Hospital Universitario Virgen Macarena, University of Seville

    Seville, Spain

  • Consorcio Hospital General Universitario de València - CHGUV

    Valencia, Spain

  • Beatson West of Scotland Cancer Centre, Glasgow (NHS Greater Glasgow & Clyde)

    Glasgow, United Kingdom

  • University College London Hospital NHS

    London, United Kingdom

  • Royal Marsden Hospital

    London, United Kingdom

  • University Hospital Southampton NHS Foundation

    Southampton, United Kingdom

  • East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre)

    Northwood, Middlesex, United Kingdom

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Bebington, Wirral, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.